January 30, 2024 — February 1, 2024 Boston, MA

Tabletop Exhibit
Plenary Session

DDR Inhibitors Summit 2024

Tempus is advancing precision medicine through the practical application of artificial intelligence in healthcare. We are pleased to participate in this conference and present how Tempus can support the development of first-in-class oncology treatments for patients.

Schedule a meeting with us
Plenary Session
January 31, 2024
live session
10:00–10:30am ET

120 Huntington Ave, Boston, MA 02116, United States
Steph LaHaye, PhD, Principal Scientist, Translational Research (Tempus)

RNA-Seq in Precision Oncology

RNA sequencing (RNA-Seq) is critical to developing the next generation of cancer therapies. Data from tumor gene expression is rich in biological information, including cellular composition, the tumor cell type of origin, the tumor microenvironment (TME), drug target overexpression, oncogenic pathway signaling, and prognostic/predictive cell states such as HRD. Because of this richness, it is vital to understand, leverage, and validate RNA at every stage of drug development, including target discovery and selection, molecular characterization across the patient journey, mechanistic studies, predicting and characterizing drug sensitization and resistance, clinical trial design, combined and multimodal therapeutic opportunities, trial recruitment, indication expansion, TME characterization, and CDx development.

Schedule a meeting with us

We'll be in touch shortly.